Intensive Care and Department of Pediatric Surgery, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Br J Clin Pharmacol. 2022 Oct;88(10):4285-4296. doi: 10.1111/bcp.14534. Epub 2020 Sep 15.
The disposition of a drug is driven by various processes, such as drug metabolism, drug transport, glomerular filtration and body composition. These processes are subject to developmental changes reflecting growth and maturation along the paediatric continuum. However, knowledge gaps exist on these changes and their clinical impact. Filling these gaps may aid better prediction of drug disposition and creation of age-appropriate dosing guidelines. We present innovative approaches to study these developmental changes in relation to drug metabolism and transport. First, analytical methods such as including liquid chromatography-mass spectrometry for proteomic analyses allow quantitation of the expressions of a wide variety of proteins, e.g. membrane transporters, in a small piece of organ tissue. The latter is specifically important for paediatric research, where tissues are scarcely available. Second, innovative study designs using radioactive labelled microtracers allowed study-without risk for the child-of the oral bioavailability of compounds used as markers for certain drug metabolism pathways. Third, the use of modelling and simulation to support dosing recommendations for children is supported by both the European Medicines Agency and the US Food and Drug Administration. This may even do away with the need for a paediatric trial. Physiologically based pharmacokinetics models, which include age-specific physiological information are, therefore, increasingly being used, not only to aid paediatric drug development but also to improve existing drug therapies.
药物的处置受多种过程驱动,如药物代谢、药物转运、肾小球滤过和身体组成。这些过程受反映儿科连续体中生长和成熟的发育变化的影响。然而,这些变化及其临床影响的知识空白仍然存在。填补这些空白可能有助于更好地预测药物处置并制定适合年龄的剂量指南。我们提出了创新的方法来研究与药物代谢和转运有关的这些发育变化。首先,包括液相色谱-质谱法在内的分析方法可用于定量分析大量蛋白质的表达,例如膜转运蛋白,只需一小部分器官组织即可实现。这对于儿科研究尤为重要,因为组织很少可用。其次,使用放射性标记示踪剂的创新研究设计允许在不影响儿童的情况下,对用作某些药物代谢途径标志物的化合物的口服生物利用度进行研究。第三,使用建模和模拟来支持儿童剂量建议的做法得到了欧洲药品管理局和美国食品和药物管理局的支持。这甚至可能无需进行儿科试验。因此,生理药代动力学模型越来越多地被用于帮助儿科药物开发,也用于改善现有的药物治疗。